The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined.
To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Design : Retrospective cohort study.
One university hospital and seven university-affiliated hospitals.
419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls).
Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-alpha2a, or recombinant interferon-alpha2b for 6 months.
The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography.
Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up.
Relapse was defined as a normal serum ALT level at the end of treatment with an increase to an abnormal level after cessation of treatment.
Nonresponse included all other ALT patterns. (...)
Mots-clés Pascal : Carcinome hépatocellulaire, Association, Hépatite virale C, Virose, Infection, Interféron, Traitement, Etude cohorte, Incidence, Facteur efficacité, Corrélation, Homme, Appareil digestif pathologie, Foie pathologie, Tumeur maligne, Antiviral, Immunothérapie
Mots-clés Pascal anglais : Hepatocellular carcinoma, Association, Viral hepatitis C, Viral disease, Infection, Interferon, Treatment, Cohort study, Incidence, Effectiveness factor, Correlation, Human, Digestive diseases, Hepatic disease, Malignant tumor, Antiviral, Immunotherapy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0362371
Code Inist : 002B02Q. Création : 25/01/1999.